IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4726
Positioning
Market Dominance
Manufacturing
Medical Equipment
$181M
Keith J. Sullivan
Neuronetics, Inc. offers non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$STIM Neuronetics, Inc. | 26 | 39 | 33 | 8 | - | - | -144.4% | -31.1% | 54.3% | -29.2% | -40.7% | 126.7% | 0.0% | 209.0x | $181M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Neuronetics, Inc. (STIM) receives a "Avoid" rating with a composite score of 26.2/100. It ranks #4726 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for STIM.
View All RatingsROIC -15.3% vs WACC 6.7% (spread -22.1%)
GM 54% vs sector 44%, OM -29% vs sector 3%
Capital turnover 0.99x, R&D intensity 4.6%
Rev growth 127%, 8yr history
Interest coverage -3.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Neuronetics, Inc. (STIM) as Avoid with a composite score of 26.2/100 at a current price of $1.26. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Neuronetics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 26.2/100 places it at rank #4726 in our full universe.
No Moat
Very High
Poor
Fair Value
Gross margins of 54% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 209% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Neuronetics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Neuronetics, Inc. with an Avoid rating, assigning a composite score of 26.2/100 and 1 out of 5 stars. Ranked #4726 of 7,333 stocks, STIM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
STIM's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -144.4% (sector avg: -1.9%), gross margins of 54.3% (sector avg: 44.1%), net margins of -40.7% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 33/100, STIM appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.82x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Neuronetics, Inc.'s investment score of 22/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 126.7% vs. a sector average of 6.7% and a return on assets of -31.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Neuronetics, Inc. is experiencing notably weak momentum with a score of just 8/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 126.7% year-over-year, while a beta of 1.76 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Neuronetics, Inc. registers a low stability score of 22/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.76 and a debt-to-equity ratio of 209.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Neuronetics, Inc.'s short interest score of 16/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.76), elevated leverage (D/E: 209.00x), micro-cap liquidity risk. At $181M (micro-cap), STIM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Neuronetics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4726 of 7,333 overall (36th percentile). Key comparisons include ROE of -144.4% trailing the -1.9% sector median and operating margins of -29.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While STIM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (8) would have the largest impact on the composite score.
ROE 7498% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 23% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1265% BELOW SECTOR MEDIAN
Neuronetics Inc. (NASDAQ: STIM) has reported preliminary unaudited financial results for the fourth quarter and full year 2025, showing significant revenue growth and positive operating cash flow. The company's revenue for Q4 2025 reached $41.8 million, an 86% year-over-year increase, and full-year revenue hit $149.2 million, up 99%. These preliminary results include adjustments related to its acquisition of Greenbrook, and full financial details are expected to be released on March 17, 2026.
Keith Sullivan, CEO of Neuronetics (NASDAQ:STIM), sold 40,976 shares of the company's stock on February 10th at an average price of $1.55, totaling $63,512.80. This transaction reduced his stake by 2.55% to 1,567,012 shares. Neuronetics currently has a consensus "Hold" rating from analysts with a target price of $7.00, and institutional investors own approximately 53.59% of the shares.
Neuronetics (NASDAQ: STIM) shares surged 41.08% in after-hours trading after the company released preliminary fourth-quarter 2025 financial results. The medical technology company reported significant revenue growth across both its NeuroStar system and clinic segments, along with positive operating cash flow. Despite the recent stock increase, STIM has seen a substantial decline over the past year and is trading near its 52-week low.
Neuronetics, Inc. announced strong preliminary financial results for Q4 and full year 2025, reporting $41.8 million in Q4 revenue with 86% year-over-year growth and $149.2 million for the full year, representing a 99% increase. The company achieved positive operating cash flow of $0.9 million in Q4 and ended the year with $34.1 million in cash. CEO Keith Sullivan highlighted solid demand for NeuroStar systems and successful clinic business optimization, with a detailed financial results conference call scheduled for March 17, 2026.
Neuronetics (NASDAQ:STIM) experienced a 4.3% drop in its stock price, trading as low as $1.90 and closing at $1.98 Monday. This decline was accompanied by a 10% increase in trading volume compared to the average session. The company recently missed its quarterly EPS estimates and reported slightly lower-than-anticipated revenue, alongside negative profitability metrics.
Above 50MA
37.18%
Net New Highs
+51081